Table 1.
Baseline characteristics
| Characteristics | CAR T-cell patients N = 280 |
|---|---|
| Demographics | |
| Age, median (range) | 64 (19-82) |
| Sex n (%) | |
| Male | 185 (66) |
| Female | 95 (34) |
| Underlying disease, n (%) | |
| Diffuse large B-cell lymphoma | 158 (56) |
| Transformed follicular lymphoma | 57 (20) |
| High-grade B-cell lymphoma | 13 (5) |
| Transformed marginal cell lymphoma | 10 (4) |
| Primary mediastinal B-cell lymphoma | 10 (4) |
| Follicular lymphoma | 9 (3) |
| Mantle cell lymphoma | 8 (3) |
| Other non-Hodgkin lymphomas* | 8 (3) |
| Transformed chronic lymphocytic leukemia | 7 (2.5) |
| Prior lines of chemotherapy, median (range) | 3 (2-10) |
| Prior HCT, n (%) | |
| Allogeneic | 9 (3) |
| Autologous | 82 (29) |
| CAR T-cell product, n (%) | |
| Axicabtagene ciloleucel | 244 (87) |
| Tisagenlecleucel | 22 (8) |
| Brexucabtagene autoleucel | 8 (3) |
| Lisocabtagene maraleucel | 6 (2) |
*
Other non-Hodgkin lymphomas: T-cell histiocytic rich diffuse B-cell lymphoma (n = 3); transformed follicular lymphoma and CLL (n = 1); gray-zone lymphoma (n = 2); transformed lymphoma not otherwise specified (n = 1); Burkitt and large B-cell lymphoma mixed phenotype (n = 1).